Avacta Group Plc (AIM:AVCT)

London flag London · Delayed Price · Currency is GBP · Price in GBX
34.25
+0.75 (2.24%)
May 8, 2025, 4:28 PM GMT+1
-24.06%
Market Cap 128.46M
Revenue (ttm) 22.62M
Net Income (ttm) -25.89M
Shares Out 383.46M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,095,668
Average Volume 1,471,925
Open 33.07
Previous Close 33.50
Day's Range 32.00 - 35.78
52-Week Range 28.83 - 86.40
Beta -0.16
RSI 44.44
Earnings Date Jun 27, 2025

About Avacta Group

Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat local... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 154
Stock Exchange London Stock Exchange AIM
Ticker Symbol AVCT
Full Company Profile

Financial Performance

In 2023, Avacta Group's revenue was 23.25 million, an increase of 140.83% compared to the previous year's 9.65 million. Losses were -24.95 million, -31.90% less than in 2022.

Financial Statements

News

Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ...

5 weeks ago - GlobeNewsWire

Avacta Group GAAP EPS of 3.80p, revenue of £11.3M

Avacta Group Plc press release (AVCTF): 1H GAAP EPS of 3.80p. Revenue of £11.3M (-5.0% Y/Y). Adjusted EBITDA loss (before non-cash and non-recurring items) of £11.1 million (H1 2023:

7 months ago - Seeking Alpha

Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life scien...

10 months ago - GlobeNewsWire

Avacta Group PLC (AVCTF) Q4 2023 Earnings Call Transcript

Avacta Group PLC (OTCPK:AVCTF) Q4 2023 Earnings Conference Call April 30, 2024 7:30 AM ET Company Participants Christina Coughlin - CEO Tony Gardiner - CFO Conference Call Participants Operator Good a...

1 year ago - Seeking Alpha